Cost-effectiveness of lenvatinib plus pembrolizumab versus chemotherapy for recurrent mismatch repair-proficient endometrial cancer after platinum-based therapy

Shayan Dioun, Ling Chen, Alexandre Buckley De Meritens, Caryn M. St. Clair, June Y. Hou, Fady Khoury-Collado, Tarah Pua, Dawn L. Hershman, Jason D. Wright

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Fingerprint

Dive into the research topics of 'Cost-effectiveness of lenvatinib plus pembrolizumab versus chemotherapy for recurrent mismatch repair-proficient endometrial cancer after platinum-based therapy'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science